CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms.

IF 2.6 4区医学 Q2 GENETICS & HEREDITY

Cancer Genomics & Proteomics Pub Date : 2025-06-26 DOI:10.21873/cgp.20521

Umar Wazir, Amber X Li, Carolyn Cai Wang, Henson Han Gao, Tracey A Martin, Wen G Jiang, Kefah Mokbel

{"title":"CD84 as a Prognostic Biomarker and Therapeutic Target in Breast Cancer: Interconnections With PDL1, CD74, and Immune Tolerance Mechanisms.","authors":"Umar Wazir, Amber X Li, Carolyn Cai Wang, Henson Han Gao, Tracey A Martin, Wen G Jiang, Kefah Mokbel","doi":"10.21873/cgp.20521","DOIUrl":null,"url":null,"abstract":"Background/aim: Cluster of differentiation 84 (CD84), a member of the signalling lymphocytic activating molecule (SLAM) family, has emerged as a potential prognostic biomarker and therapeutic target in breast cancer. This study explored CD84 expression and its correlation with clinicopathological features in a well-characterised cohort.Materials and methods: Using quantitative real-time PCR, mRNA expression levels of CD84 and related molecules, including PDL1, CD74, and other immune tolerance markers, were analysed.Results: The findings reveal that elevated CD84 expression predicts poor overall survival, independent of conventional prognostic factors such as the Nottingham Prognostic Index (NPI). Notably, a combined signature of CD84, CD48, VAV1, and CTNNB1 demonstrated stronger prognostic power than individual markers. CD84 exhibited significant correlations with immunosuppressive molecules, including PDL1 and CD74, underscoring its role in fostering immune tolerance within the tumour microenvironment.Conclusion: CD84 may mediate an immunosuppressive phenotype, facilitating immune evasion in breast cancer. This highlights its potential as a therapeutic target, particularly in triple-negative breast cancer, to overcome immune resistance and enhance treatment efficacy.","PeriodicalId":9516,"journal":{"name":"Cancer Genomics & Proteomics","volume":"22 4","pages":"557-563"},"PeriodicalIF":2.6000,"publicationDate":"2025-06-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12216572/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Genomics & Proteomics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/cgp.20521","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"GENETICS & HEREDITY","Score":null,"Total":0}

引用次数: 0

Abstract

Background/aim: Cluster of differentiation 84 (CD84), a member of the signalling lymphocytic activating molecule (SLAM) family, has emerged as a potential prognostic biomarker and therapeutic target in breast cancer. This study explored CD84 expression and its correlation with clinicopathological features in a well-characterised cohort.

Materials and methods: Using quantitative real-time PCR, mRNA expression levels of CD84 and related molecules, including PDL1, CD74, and other immune tolerance markers, were analysed.

Results: The findings reveal that elevated CD84 expression predicts poor overall survival, independent of conventional prognostic factors such as the Nottingham Prognostic Index (NPI). Notably, a combined signature of CD84, CD48, VAV1, and CTNNB1 demonstrated stronger prognostic power than individual markers. CD84 exhibited significant correlations with immunosuppressive molecules, including PDL1 and CD74, underscoring its role in fostering immune tolerance within the tumour microenvironment.

Conclusion: CD84 may mediate an immunosuppressive phenotype, facilitating immune evasion in breast cancer. This highlights its potential as a therapeutic target, particularly in triple-negative breast cancer, to overcome immune resistance and enhance treatment efficacy.

查看原文本刊更多论文

CD84作为乳腺癌预后生物标志物和治疗靶点：与PDL1、CD74和免疫耐受机制的相互联系

背景/目的：CD84 （Cluster of differentiation 84, CD84）是信号淋巴细胞激活分子（signaling lymphocytic activating molecule， SLAM）家族的一员，已成为乳腺癌预后的潜在生物标志物和治疗靶点。本研究在一个特征明确的队列中探讨了CD84的表达及其与临床病理特征的相关性。材料与方法：采用实时荧光定量PCR技术，分析CD84及相关分子PDL1、CD74等免疫耐受标志物的mRNA表达水平。结果：研究结果表明，CD84表达升高预示着总生存期较差，与诺丁汉预后指数（NPI）等传统预后因素无关。值得注意的是，CD84、CD48、VAV1和CTNNB1的联合标记比单个标记显示出更强的预后能力。CD84表现出与免疫抑制分子（包括PDL1和CD74）的显著相关性，强调了其在肿瘤微环境中促进免疫耐受的作用。结论：CD84可能介导乳腺癌的免疫抑制表型，促进免疫逃避。这突出了其作为治疗靶点的潜力，特别是在三阴性乳腺癌中，可以克服免疫抵抗并提高治疗效果。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Genomics & Proteomics ONCOLOGY-GENETICS & HEREDITY

CiteScore

5.00

自引率

8.00%

发文量

期刊介绍： Cancer Genomics & Proteomics (CGP) is an international peer-reviewed journal designed to publish rapidly high quality articles and reviews on the application of genomic and proteomic technology to basic, experimental and clinical cancer research. In this site you may find information concerning the editorial board, editorial policy, issue contents, subscriptions, submission of manuscripts and advertising. The first issue of CGP circulated in January 2004. Cancer Genomics & Proteomics is a journal of the International Institute of Anticancer Research. From January 2013 CGP is converted to an online-only open access journal. Cancer Genomics & Proteomics supports (a) the aims and the research projects of the INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH and (b) the organization of the INTERNATIONAL CONFERENCES OF ANTICANCER RESEARCH.